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Extracts of the leaves of the plant, Stevia rebaudiana Bertoni (SrB), have been used for many years in traditional South American treatment of diabetes. Oral intake of SrB extracts slightly suppresses plasma glucose during an oral glucose tolerance test in healthy subjects. 4 A 35% reduction in blood glucose is also observed in diabetic subjects after oral intake of SrB extracts. 5 However, we only have limited knowledge of which substance(s) are active. A possible candidate is the glycoside stevioside, a white crystalline material with the elemental composition C 38 H 60 O 18 , which makes up the largest proportion of the dry matter of SrB. Thus stevioside in vitro exerts a direct insulinotropic action in both isolated mouse islets and the clonal ␤-cell line, INS-1. 6, 7 Furthermore, we demonstrated in a pilot study in vivo that an acute bolus injection of stevioside had antihyperglycemic, insulinotropic, and glucagonostatic effects in the anesthetized, diabetic GotoKakizaki (GK) rats. 8 This is a non-obese animal model of type 2 diabetes characterized by a deficient insulin response to glucose in vivo and in vitro, as well as insulin resistance. [9] [10] [11] [12] Interestingly, it has been found that stevioside induces blood pressure reduction in hypertensive nondiabetic rats 13 and also in nondiabetic hypertensive subjects. 14 The aims of the present study were to test if long-term administration of stevioside possesses dual beneficial qualities, ie, antihyperglycemic effects and blood pressure suppression in type 2 diabetes. We specifically tested whether stevioside (1) has antihyperglycemic properties and lowers the blood pressure in the diabetic GK rat after long-term oral treatment and (2) elicits hypoglycemia in the fasting state in the GK and Wistar rats when given as a bolus injection. Furthermore, we used the high-density oligonucleotide microarray technology to explore the mechanisms underlying the insulinotropic effect of stevioside and the aglucon, steviol, by using the clonal ␤-cell line, INS-1.
MATERIALS AND METHODS

Animals
We used adult male GK (originally obtained from Takeda Chemical, Tokyo, Japan and bred locally; age, 20 weeks; weight, 250 to 320 g) and male Wistar rats (Bomholtgaard Breeding and Research Centre, Ry, Denmark; age, 15 weeks; weight, 250 to 350 g). The animals were kept on a standard pellet diet and had tap water ad libitum and a light cycle of 12 hours/12 hours. Before the experiments, food was withheld from the rats for 12 hours. The experiments were performed in accordance with the guidelines of the Danish Council on Animal Care.
Intra-Arterial Glucose Tolerance Test Performed in GK Rats After Long-Term Stevioside Treatment
The glucoside stevioside (19-O-␤-glucopyranosyl-13-O [␤-glucopyranosyl (1-2)]-␤ -glucopyranosyl-steviol (purity Ͼ 99.6%) (Sigma Chemical, St Louis, MO) was added to the tap water and given to the GK rats (n ϭ 20) at a dose of 0.025 g ⅐ kg Ϫ1 ⅐ d Ϫ1 for a period of 6 weeks. The stevioside molecule is composed of steviol, a diterpenic carboxylic alcohol, and 3 D-glucose molecules. The control group received the same molecular amount of glucose as content in the stevioside group (0.0167 g ⅐ kg
). At week 5, the GK rats were anesthetized by subcutaneous (SC) injection (1 mL ⅐ kg Ϫ1 rat) of a mixture consisting of 0.08 mg/mL phentanyl citrate, 2.5 mg/mL phluanisone (Janssen Pharmaceutica, Beerse, Belgium) and 1.25 mg/mL midazolame (Dumex-Alpharma, Oslo, Norway). In the frontal part of the neck, a midline incision was performed and the right carotic artery was isolated. The cephalic part of the artery was closed by suture and the catheter was held in position by ligatures. A hole in the artery was made caudal to the closing suture and a catheter (Tygon Microbore Tubing, Norton Performance Plastics [Akron, OH]; inner diameter [id] 0.40 mm, outer diameter [od] 0.78 mm) was inserted 30 mm into the artery and held in position by ligatures. The free end of the catheter was exteriorised at the neck leaving 2.5 cm of the catheter outside the animal. The catheter was filled with 0.9% saline containing 10 U/mL heparin (Løvens Kemiske Fabrik, Ballerup, Denmark) and closed with a fishing line inserted into the lumen. After surgery, the animals were given 0.08 mg Naloxone intramuscularly (IM) as antidote (DuPont Pharmaceuticals, Hertfordshire, UK). Animals were caged individually with free access to food and water. The catheters were flushed daily with 0.2 mL saline/heparin to keep them open. After 6 days' recovery, an intra-arterial glucose tolerance test (IAGTT) (2.0 g ⅐ kg
Ϫ1
) was performed. Food was withheld from the animals for 12 hours (water ad libitum) before the experiments starting at 8 PM. The animals were freely moving in separate plastic cylinders. The intra-arterial catheter was connected to a polyethylene tube system (PE20, Intramedic, Becton Dickinson, Sparks, MD) allowing blood sampling and infusion. Blood samples were drawn at time points from Ϫ15 to 180 minutes. Immediately after the 0 minute sample D-glucose (2 g ⅐ kg Ϫ1 dissolved in 0.9% saline) was administered as a bolus injection over 20 seconds. Blood samples (300 L) were drawn in chilled tubes containing 3 L aprotinin/heparin mix (7.7 mg/mL aprotinin and 2,300 IU/mL heparin), samples were then centrifuged (10 minutes, 4°C, 4,000 rpm), and plasma was frozen for subsequent analysis of insulin, glucose, and glucagon. Blood was replaced by isotonic saline to avoid volume depletion. 15 
Measurements of Tail Blood Pressure During Long-Term Treatment With Stevioside
The tail-blood pressure was determined every week during the 6-week period using the TRN005 Kent Instrumentation Amplifier (Scandidact, Kvistgaard, Denmark) to measure the diastolic and systolic blood pressure.
Intra-Arterial Bolus Injection of Stevioside in Conscious Wistar and GK Rats in the Fasting State
Acute experiments with intra-arterial infusion of stevioside alone were performed in the fasting state in normal Wistar (n ϭ 22) and diabetic GK rats (n ϭ 12) having undergone the same surgical procedure as described above. No oral treatment with stevioside was given before the experiments. Stevioside (0.2 g ⅐ kg Ϫ1 ) alone was given as a bolus injection 1 week after the day of catheter insertion and after 12 hours of fasting. Saline infusion served as control.
Gene Expression Profiles and Insulin Content of INS-1 Cells
The mechanism of action of stevioside and steviol was examined by culturing the clonal pancreatic ␤-cell line, INS-1, cells in the presence or absence of 1 mol/L stevioside or steviol at 11 mmol/L glucose for 24 hours. INS-1 cells (passage 48 to 50) were cultured in RPMI 1640 supplemented with HEPES (10 mmol/L), sodium pyruvate (1 mmol/L), and ␤-mercaptoethanol (5 mol/L). 16 The cells were collected for insulin content determination and RNA extraction. To ensure that the samples were representative and to reduce preanalysis variation, 3 extracted total RNA samples were pooled from the same culture conditions in an equal amount and used for further investigation of the gene expression profile. The methods were identical to those described previously. 16 Briefly, investigation of the expression of 8,740 genes or expressed sequence tags (ESTs) proceeded through the following steps: (1) 100 g total RNA was used for mRNA preparation. Poly (A)ϩ RNA was isolated by an oligo-dT selection step (Oligotex kit, Qiagen, Valencia, CA). (2) A total of 1 g mRNA was used as starting material for the cDNA preparation. Labeled cRNA was prepared using the MEGAscript In Vitro transcription (IVT) kit (Ambion, Austin, TX). (3) A total of 10 g cRNA were fragmented and loaded onto the Affymetrix probe array cartridge rat U34A gene chip. (4) The biotinylated cRNA was stained with a streptavidin-phycoerythrin conjugate. (5) The probe arrays were scanned at 560 nm by a scanning confocal microscope with an argon ion laser as the excitation source (made for Affymetrix by Hewlett Packard). (6) The readings from the quantitative scanning were analyzed by the Affymetrix gene chips analysis software. Two chips were done per sample. For each gene or EST, approximately 20 pairs of probes (complemented to different parts of mRNA of a gene) were used to measure the level of expression. One pair of probes consists of a perfect match (PM) probe and mismatch (MM) probe (1 MM nucleotide in the middle of sequence). The latter is used to determine the background signal after hybridization. A probe pair is considered positive when the intensity of PM minus the intensity of MM and the ratio of the intensity of PM to the intensity of MM are greater than or equal to the statistical gene expression. The difference of expression was measured by comparing the difference in intensity of all pairs of probes between samples for each gene. 16 The number of genes that changed expression depended on the cut-off values set (significant level). The cut-off values are arbitrary. The larger the numerical sort score (SS; a value based on both fold change and average difference change), the more significant or reliable is the measured difference in expression of gene between the experimental group and the control group. The genes that had changed in expression Ն 3-fold and EST with an SS of 0.65 or more to stevioside and steviol were presented.
Assays
Blood samples were centrifuged (10 minutes, 4°C, 4,000 rpm), and glucose was determined using the GLU MPR Glucose/GOD-PAP method (Boehringer Mannheim GmbH, Mannheim, Germany). Plasma insulin and glucagon were analyzed by radioimmunoassay (RIA) kits (Linco Research, St Charles, MO). The antibody in the glucagon kit is specific for pancreatic glucagon and does not cross react with other islet polypeptides. The sensitivity of the glucagon assay is 20 pg/mL. For the insulin secretion study, insulin was analyzed by RIA using a guinea pig antiporcine insulin antibody (Novo Nordisk, Bagsvaerd, Denmark) and mono-125 I(Tyr A14)-labeled human insulin (Novo Nordisk) as tracer and porcine insulin as standard (Novo Nordisk). The separation of bound and free radioactivity was performed using ethanol.
Statistical Analysis
Statistical analysis was performed by Student's unpaired t test. Differences were considered significant at P Ͻ .05. If not indicated elsewhere, data are presented as mean Ϯ SEM. The incremental area was calculated as the area under the curve above basal (IAUC). Total area under the curve (TAUC) was calculated as the area above zero. Figure 1 shows that there was no significant difference in fasting plasma glucose or plasma insulin levels between the stevioside and control group (n ϭ 10) of conscious GK rats before glucose injection (2.0 g ⅐ kg Ϫ1 ) (Fig 1A) . (Fig 1C) .
RESULTS
Effects of Long-Term Treatment With Stevioside on Intra-Arterial Glucose Tolerance Tests in Type 2 Diabetic GK Rats
Effects of Long-Term Treatment With Stevioside on Blood Pressure and Body Weight in Type 2 Diabetic GK Rats
As illustrated in Fig 2, initial systolic and diastolic blood pressures were similar in the 2 groups: systolic/diastolic blood pressure. After the 6-week study period, a significant difference in systolic/diastolic blood pressure was observed: (mean Ϯ Stevioside caused a progressive lowering of blood pressure from week 1 and onward (Fig 2A) . Stevioside had no significant effect on body weight (mean Ϯ SEM).
Effects of a Bolus Infusion of Stevioside on Blood Glucose and Insulin Levels in Conscious Fasting Diabetic GK Rats
As shown in Fig 3, a bolus (Fig 3) . As expected, the fasting blood glucose level of these animals was lower than that of the GK rats participating in the long-term stevioside treatment because they were 5 weeks older on the day of the IAGTT (Fig 1) . 
Effects of a Bolus Infusion of Stevioside on Blood Glucose and Insulin Levels in Conscious Fasting Wistar Rats
Insulin Content in INS-1 Cells Treated With Stevioside
The INS-1 cells were incubated for 24 hours with 11 mmol/L glucose with or without stevioside and steviol, respectively. Stevioside and steviol (1 mol/L) significantly (P Ͻ .05) increased the insulin content in the clonal ␤-cell line, INS-1 (Fig 5) .
The Effect of Stevioside on the Gene Expression Profile in INS-1 Cells
Thirty-five genes and 19 ESTs (not shown) changed expression more than 3 times in response to stevioside (Table 1) . Among them, the proinsulin gene was upregulated 3.8 times. Interestingly, the liver type pyruvate gene, acetyl-coenzyme A carboxylase, and the fatty acid synthetase gene were upregulated. In contrast, genes involved in fatty acid oxidation, ie, the carnitine palmitoyltransferase I (CPT-1) gene, the long-chain acyl-CoA dehydrogenase gene, the 3-oxoacyl-CoA thiolase gene, and the cytosolic epoxide hydrolase gene were all downregulated. Interestingly, phosphodiesterase I (PDE 1) was also downregulated in the INS-1 cells. The aglucon of stevioside, steviol (1 mol/L), induced similar changes on gene expression as stevioside.
DISCUSSION
We tested the hypothesis that the combined antihyperglycemic and blood pressure-lowering effects were harbored in the diterpene glycoside stevioside, a main component of the dry matter of leaves of SrB. This study is the first to demonstrate that long-term oral stevioside treatment has antihyperglycemic and blood pressure-lowering effects in the diabetic GK rat where it stimulated the first phase insulin secretion and suppressed the glucagon levels in vivo. Stevioside induced the ␤-cell genes involved in the glycolysis and nutrient-sensing mechanisms. In the fasting state, no acute hypoglycemic action was discovered after a bolus injection of stevioside in the normal Wistar or in the diabetic GK rat. Stevioside consists of a complex of 3 glucose molecules and 1 molecule of the steviol aglucone, a diterpenic carboxylic alcohol. 17, 18 In a previous pilot study, a single bolus injection of stevioside caused steadily increasing insulin concentrations and a suppression of glucagon during an intravenous (IV) glucose tolerance test (IVGTT) in anesthetized GK rats. 8 In this previous study, stevioside did not, as in the present study, enhance the first-phase insulin response in the anesthetized GK rats. 8 However, data obtained in anesthetized animals should be interpreted with caution as anesthesia may significantly affect glucose and insulin levels, as well as other hormones.
Type 2 diabetes is a chronic metabolic disorder that not only results from insulin resistance and defect in first phase insulin secretion, but is also characterized by a relative glucagon excess and a pancreatic ␣-cell dysfunction. 19 The suppression of circulating glucagon concentrations reduces blood glucose levels 20 supporting that agents inhibiting the glucagon secretion or action are beneficial for patients with diabetes. In experimental diabetes, an abnormal ␣-cell function is characterized by an impaired response to glucose and certain glucose metabolites that probably results from a specific defect in glucose recognition. 21 The abnormal ␣-cell function seems not to be ascribed to an insulin deficiency per se, but rather to an abnormal metabolic state secondary to insulin deficiency. 22 Interestingly, plasma glucagon decreased initially during the IAGTT in the stevioside-treated GK group compared with the control group. The glucagonostatic effect of stevioside treatment is therefore presumably caused either via a direct inhibitory action on the glucagon-producing ␣ cells or an indirect action via either an improved glucose recognition or an insulin-induced suppression of glucagon. We addressed the question whether stevioside in the fasting state may cause hypoglycemia like sulphonylureas and hence become a threat to the diabetic subject by conducting the experiments in fasting, conscious GK, and Wistar rats. We demonstrated that a bolus injection of stevioside in the fasting state did not cause hypoglycemia in the normal Wistar or the diabetic GK rat. This is supported by our previous demonstrations in vitro that the effects of stevioside fade at glucose concentrations comparable with normoglycemia. 6, 7 Interestingly, the long-term administration in vivo in GK rats had no effect on fasting blood glucose, insulin, and glucagon, while it markedly improved the glucose tolerance. The reason could be that the GK rats only display a rather mild fasting hyperglycemia. We have tried to gain insight into the mechanisms of action of stevioside using the INS-1 cells. We are aware that it is not possible to make farreaching extrapolations from the in vitro effects to the in vivo situation. Chronic exposure of INS-1 cells to stevioside increased the content of proinsulin mRNA and insulin, which may have contributed to the increased glucose-stimulated insulin secretion. 6, 7 Previously, we have demonstrated that stevioside does not affect the adenosine triphosphate (ATP)-sensitive potassium channels in the ␤ cells. 7 It is well known that malonyl-CoA plays a key role in the nutrient-sensing mechanism of ␤ cells. Glucose activation of acetyl-CoA carboxylase triggers a rapid production of malonyl-CoA, which inhibits CPT-1 and the importation of fatty acyl-CoA into the mitochondria for oxidation. The increase in cytosolic long-chain fatty acyl-CoA leads to the exocytosis of insulin. 23 Interestingly, stevioside upregulated the expression of the liver type of pyruvate kinase (L-PK) and acetyl-CoA carboxylase, whereas it downregulated the expressions of CPT-1, long-chain acyl-CoA dehydrogenase, cytosolic epioxide hydrolase, and 3-oxoacyl-CoA thiolase. These modifications favor the augmentation of the longchain fatty acyl-CoA during glucose challenge. Therefore, the improved insulin secretion by stevioside may attribute to the induction of genes involved in glycolysis and the improvement of nutrient-sensing mechanisms. It should be kept in mind that because there is a low expression of acetyl CoA-carboxylase and fatty acid synthetase in islets, the de novo fatty acid synthesis may not result in fat accumulation during long-term treatment. Moreover, the stevioside-induced counteraction of the abnormal insulin and glucagon secretion might inhibit lipolysis in adipose tissue and reduce the accumulation of fat in nonadipose tissue. Further experiments are needed to clarify this question. The downregulation of PDE1 may contribute to the improvement of insulin secretion secondary to increased intracellular cyclic adenosine monophosphate (cAMP) levels, an important physiologic amplifier of the glucose-induced insulin secretion. Pancreatic islets from rats, mice, and humans express functional PDE1, PDE3, PDE4, and PDE5, as well as an IBMXresistant cAMP PDE8. 24 Finally, the present study also revealed an increase in the A2b-adenosine receptor, which is involved in the adenyl cyclase activation increasing the synthesis of cAMP. 25 Stevioside increases the expression of glucose responsive genes. The mode of action is not clear because the aglucon, steviol, has equal effects as stevioside. It is unlikely that the action is mediated via the glucose residues, but may be ascribed to the carboxylic alcohol and/or the bicyclo [3,2,1] octane C/D ring.
The long-term prognosis of type 2 diabetes relies not only on the treatment of hyperglycemia, but also on the coexistence of hypertension, dyslipidemia, obesity, sedentariness, and smoking as delineated in the United Kingdom Prospective Diabetes Study (UKPDS). 1, 2, 26, 27 Consequently, the pharmacologic treatment of type 2 diabetes should also aim to lower blood pressure and lipid concentrations. The present study demonstrated that long-term stevioside treatment had a significant blood pressure-lowering effect from week 1 and onwards. Our results support the previously demonstrated blood pressure reduction in nondiabetic rats. 28 Recently, a blood pressurelowering effect has also been reported in nondiabetic subjects with hypertension being treated for 1 year with stevioside. 14 No side effects or beneficial effects on lipid or glucose were reported. We were not surprised to learn that stevioside had no effect on blood glucose because the subjects were normoglycemic, nondiabetic subjects, but it would be interesting to learn whether daily administration of stevioside to patients suffering from the metabolic syndrome would improve their lipid levels secondary to better glycemic control. Although the mechanism underlying the antihypertensive effect of stevioside is not clear, it has been demonstrated that the hypotensive response to stevioside appears to occur through a calcium antagonist mechanism similar to that of verapamil. 29, 30 In conclusion, long-term oral stevioside treatment improves first-phase insulin response, suppresses glucagon levels, and has antihyperglycemic effects in the diabetic GK rat. Bolus injections of stevioside do not elicit hypoglycemia in conscious normal Wistar or diabetic GK rats. The modification of gene expression involving insulin synthesis, glucose, and fatty acid metabolism may contribute to the beneficial metabolic effect in diabetic animals. Additionally, stevioside accomplishes a pronounced suppression of blood pressure in the GK rat. Whether stevioside may serve as a "new" medicament for the treatment or prevention of the metabolic syndrome with actions on 2 or more of the clinical features remains to be elucidated.
